Business Context and Reporting Period
This Form 8-K, filed on August 30, 2022, reports the consummation of a business combination between Vivani Medical, Inc. (formerly Second Sight Medical Products, Inc.) and Nano Precision Medical, Inc. (NPM). The transaction closed on August 30, 2022, resulting in NPM becoming a wholly-owned subsidiary of the Company. Concurrently, the Company changed its name to "Vivani Medical, Inc." and its ticker symbol on the Nasdaq Capital Market changed from "EYES" to "VANI" effective August 31, 2022.
Key Financial Metrics and Capital Structure
The filing details the equity structure post-merger but does not provide specific revenue, profit, or cash flow figures for the combined entity in this text; such data is referenced in attached exhibits.
- Shares Issued: 37,589,967 shares of Common Stock were issued to former NPM shareholders.
- Total Outstanding Shares: Approximately 50,726,329 shares immediately after the merger.
- Ownership Distribution: Former NPM securityholders own approximately 74.1% of the issued and outstanding Common Stock.
- Reverse Stock Split: A 3-for-1 reverse stock split was effected on August 19, 2022, prior to the merger closing.
- Lock-Up Agreements: 18,002,685 shares are subject to 180-day lock-up agreements for directors, officers, and significant holders of NPM.
Material Changes Versus Prior Period
The primary material change is the acquisition of NPM, which fundamentally alters the Company's business focus and capitalization. Key changes include:
- Corporate Identity: Legal name changed from Second Sight Medical Products, Inc. to Vivani Medical, Inc.
- Trading Symbol: Changed from "EYES" to "VANI"; warrants ("EYESW") are projected to be voluntarily delisted.
- Board Composition: The Board was reduced to five members. Former directors Jonathan Will McGuire and Matthew Pfeffer resigned. Adam Mendelsohn was appointed as a new director.
- Executive Leadership: Scott Dunbar (Acting CEO) and Edward Sedo (Acting Chief Accounting Officer) resigned. New officers appointed include Adam Mendelsohn (CEO), Brigid A. Makes (CFO), Truc Le (COO), Donald Dwyer (CBO), and Lisa Porter (CMO).
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance or forward-looking revenue projections. However, it notes the following contingencies and risks:
- Closing Condition Waiver: The Company waived the requirement for NPM to terminate a Legacy Shareholders Agreement prior to closing. This was permissible because the merger eliminated the NPM shares subject to the agreement.
- Related Party Transactions: Certain directors had pre-existing material relationships with NPM involving potential conflicts of interest, as detailed in the Prospectus.
- Warrant Delisting: The Company intends to voluntarily delist its warrants from the Nasdaq Capital Market.
Investor Verification Checklist
- Verify the unaudited pro forma condensed combined financial information (Exhibit 99.3) to understand the combined entity's financial position.
- Review the unaudited condensed consolidated financial statements of NPM (Exhibit 99.2) for the six months ended June 30, 2022.
- Confirm the terms of the Lock-Up Agreements (Exhibit 10.1) and the specific exclusions for Aaron Mendelsohn and Dean Baker.
- Examine the Prospectus (Form S-4) for details on executive compensation and related party transactions involving directors.
- Monitor the status of the voluntary delisting of the Company's warrants.